SC 13G/A 1 ea155134-13ga1lav_inhibrx.htm AMENDMENT NO. 1 TO SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No.1)*

Inhibrx, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

45720L107

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☐

Rule 13d-1(c)

☒

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45720L107

13G/A

Page 2 of 8 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) LAV Summit Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

SOLE VOTING POWER

151,992 shares, except that Yi Shi, the managing partner of LAV Summit Limited, may be deemed to have shared power to vote these shares.

SHARED VOTING POWER

See response to row 5.

SOLE DISPOSITIVE POWER

151,992 shares, except that Yi Shi, the managing partner of LAV Summit Limited, may be deemed to have shared power to dispose of these shares.

SHARED DISPOSITIVE POWER

See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 151,992
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4% (1)
12	TYPE OF REPORTING PERSON OO

(1)

This percentage is calculated based upon 37,954,989 shares of common stock outstanding of Inhibrx, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 9, 2021.

CUSIP No. 45720L107

13G/A

Page 3 of 8 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Yi Shi
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

SOLE VOTING POWER

0 shares.

SHARED VOTING POWER

151,992 shares which are directly owned by LAV Summit Limited. Yi Shi, the managing partner of LAV Summit Limited, may be deemed to have shared power to vote these shares.

SOLE DISPOSITIVE POWER

0 shares.

SHARED DISPOSITIVE POWER

151,992 shares which are directly owned by LAV Summit Limited. Yi Shi, the managing partner of LAV Summit Limited, may be deemed to have shared power to dispose of these shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 151,992
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4% (1)
12	TYPE OF REPORTING PERSON IN

(1)	This percentage is calculated based upon 37,954,989 shares of common stock outstanding of Inhibrx, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 9, 2021.

CUSIP No. 45720L107

13G/A

Page 4 of 8 Pages

Item 1(a)

Name of Issuer:

Inhibrx, Inc. (the “Issuer”)

Item 1(b)

Address of Issuer’s Principal Executive Offices:

1025 N. Torrey Pines Road, Suite 200

La Jolla, CA 92037

Item 2(a)

Name of Persons Filing:

This Statement is filed by LAV Summit Limited and Dr. Yi Shi. The foregoing entities and individual are collectively referred to as the “Reporting Persons.”

Dr. Shi is the managing partner of LAV Summit Limited, and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by LAV Summit Limited.

Item 2(b)

Address of Principal Business Office or, If None, Residence:

The address for LAV Summit Limited and Dr. Shi is Room 606-7, St. George’s Building,
2 Ice House Street, Central, Hong Kong.

Item 2(c)

Citizenship:

LAV Summit Limited is a British Virgin Islands business company. Dr. Shi is a United States citizen.

Item 2(d)

Title of Class of Securities:

Common Stock, $0.0001 par value per share

Item 2(e)

CUSIP Number:

CUSIP #45720L107

Item 3.

Not applicable.

Item 4.

Ownership

The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Persons is provided as of December 31, 2021:

(a)

Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class:

See Row 11 of cover page for each Reporting Person.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

CUSIP No. 45720L107

13G/A

Page 5 of 8 Pages

(ii)

Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

Item 5.	Ownership of Five Percent or Less of a Class Not applicable.

Item 6.	Ownership of More Than Five Percent on Behalf of Another Person Not applicable.

Item 7.	Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

	Not applicable.

Item 8.	Identification and Classification of Members of the Group

	Not applicable.

Item 9.	Notice of Dissolution of Group

	Not applicable.

Item 10.	Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

CUSIP No. 45720L107

13G/A

Page 6 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2022

	LAV Summit Limited

	By:	/s/ Yi Shi
	Name:	Yi Shi
	Title:	Managing Partner

	Yi Shi

	/s/ Yi Shi
	Yi Shi

CUSIP No. 45720L107

13G/A

Page 7 of 8 Pages

EXHIBIT INDEX

Exhibit		Found on Sequentially Numbered Page
Exhibit A: Agreement of Joint Filing		8

CUSIP No. 45720L107

13G/A

Page 8 of 8 Pages

EXHIBIT A

Agreement of Joint Filing

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Inhibrx, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

Dated: February 9, 2022

	LAV Summit Limited

	By:	/s/ Yi Shi
	Name:	Yi Shi
	Title:	Managing Partner

	Yi Shi

	/s/ Yi Shi
	Yi Shi

SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)